Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study
© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aims: Peginterferon has demonstrated effectiveness in clinical trials in patients with chronic hepatitis B (CHB). However, its efficacy in real-life settings remains unclear. We inv...
Saved in:
Main Authors: | Phunchai Charatcharoenwitthaya, Wattana Sukeepaisarnjaroen, Teerha Piratvisuth, Satawat Thongsawat, Theeranun Sanpajit, Soonthorn Chonprasertsuk, Woramon Jeamsripong, Ekawee Sripariwuth, Piyawat Komolmit, Tanisa Patcharatrakul, Rattana Boonsirichan, Chalermrat Bunchorntavakul, Supoj Tuntipanichteerakul, Tawesak Tanwandee |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84996565533&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56029 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study
by: Phunchai Charatcharoenwitthaya, et al.
Published: (2018) -
Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study
by: Charatcharoenwitthaya P., et al.
Published: (2017) -
Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: A multicentre study
by: Kessarin Thanapirom, et al.
Published: (2018) -
Vitamin D-binding protein gene polymorphism predicts pegylated interferon-related HBsAg seroclearance in HBeAg-negative Thai chronic hepatitis B patients: A multicentre study
by: Kessarin Thanapirom, et al.
Published: (2019) -
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study
by: Phunchai Charatcharoenwitthaya, et al.
Published: (2020)